These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 2513474)

  • 1. Involvement of sulfhydryl residues in aldose reductase-inhibitor interaction.
    Bhatnagar A; Liu S; Das B; Srivastava SK
    Mol Pharmacol; 1989 Dec; 36(6):825-30. PubMed ID: 2513474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition kinetics of human kidney aldose and aldehyde reductases by aldose reductase inhibitors.
    Bhatnagar A; Liu SQ; Das B; Ansari NH; Srivastava SK
    Biochem Pharmacol; 1990 Mar; 39(6):1115-24. PubMed ID: 2157439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidized aldose reductase: in vivo factor not in vitro artifact.
    Grimshaw CE; Lai CJ
    Arch Biochem Biophys; 1996 Mar; 327(1):89-97. PubMed ID: 8615700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetic and spectroscopic evidence for active site inhibition of human aldose reductase.
    Nakano T; Petrash JM
    Biochemistry; 1996 Aug; 35(34):11196-202. PubMed ID: 8780524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldose reductase inhibitors and prevention of galactose cataracts in rats.
    Unakar N; Tsui J; Johnson M
    Invest Ophthalmol Vis Sci; 1989 Jul; 30(7):1623-32. PubMed ID: 2545646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of human brain aldose reductase and hexonate dehydrogenase by alrestatin and sorbinil.
    O'Brien MM; Schofield PJ; Edwards MR
    J Neurochem; 1982 Sep; 39(3):810-4. PubMed ID: 6808090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldehyde and aldose reductases from human placenta. Heterogeneous expression of multiple enzyme forms.
    Vander Jagt DL; Hunsaker LA; Robinson B; Stangebye LA; Deck LM
    J Biol Chem; 1990 Jul; 265(19):10912-8. PubMed ID: 2113526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purification of aldose reductase from human placenta and stabilization of the inhibitor binding site.
    Vander Jagt DL; Stangebye LA; Hunsaker LA; Eaton RP; Sibbitt WL
    Biochem Pharmacol; 1988 Mar; 37(6):1051-6. PubMed ID: 3128293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of inhibition of aldose reductase by menadione (vitamin K3).
    Bhatnagar A; Liu SQ; Petrash JM; Srivastava SK
    Mol Pharmacol; 1992 Nov; 42(5):917-21. PubMed ID: 1435755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galactose cataract prevention with sorbinil, an aldose reductase inhibitor: a light microscopic study.
    Datiles M; Fukui H; Kuwabara T; Kinoshita JH
    Invest Ophthalmol Vis Sci; 1982 Feb; 22(2):174-9. PubMed ID: 6799419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The distribution of aldose reductase and aldehyde reductase II in different regions of bovine lens.
    Liu S; Das B; Srivastava SK
    Lens Eye Toxic Res; 1989; 6(3):415-30. PubMed ID: 2518623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human placenta aldose reductase. Forms sensitive and insensitive to inhibition by alrestatin.
    Maragoudakis ME; Wasvary J; Hankin H; Gargiulo P
    Mol Pharmacol; 1984 May; 25(3):425-30. PubMed ID: 6427599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical therapy in the prevention of cataract.
    Brown NA; Bron AJ
    Trans Ophthalmol Soc U K (1962); 1985; 104 ( Pt 7)():748-54. PubMed ID: 3938085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, absolute configuration, and conformation of the aldose reductase inhibitor sorbinil.
    Sarges R; Bordner J; Dominy BW; Peterson MJ; Whipple EB
    J Med Chem; 1985 Nov; 28(11):1716-20. PubMed ID: 3934383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of cysteine residues for the stability and catalytic activity of human pancreatic beta cell glucokinase.
    Tiedge M; Richter T; Lenzen S
    Arch Biochem Biophys; 2000 Mar; 375(2):251-60. PubMed ID: 10700381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in the susceptibility of various aldose reductases to inhibition. II.
    Kador PF; Kinoshita JH; Tung WH; Chylack LT
    Invest Ophthalmol Vis Sci; 1980 Aug; 19(8):980-2. PubMed ID: 6773903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldose and aldehyde reductases: structure-function studies on the coenzyme and inhibitor-binding sites.
    El-Kabbani O; Old SE; Ginell SL; Carper DA
    Mol Vis; 1999 Sep; 5():20. PubMed ID: 10493777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutathione dependent modification of bovine lens aldose reductase.
    Cappiello M; Voltarelli M; Giannessi M; Cecconi I; Camici G; Manao G; Del Corso A; Mura U
    Exp Eye Res; 1994 Apr; 58(4):491-501. PubMed ID: 7925685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of hexonate dehydrogenase and aldose reductase from bovine retina by sorbinil, statil, M79175 and valproate.
    Poulsom R
    Biochem Pharmacol; 1986 Sep; 35(17):2955-9. PubMed ID: 3091036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors.
    Jacobson M; Sharma YR; Cotlier E; Hollander JD
    Invest Ophthalmol Vis Sci; 1983 Oct; 24(10):1426-9. PubMed ID: 6413448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.